Personalized radiotherapy guided by PET/CT with intensity modulated techniques in patients with non-small cell Lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400081896

Enrollment

Unknown

Registered

2024-03-14

Start date

2012-11-01

Completion date

Unknown

Last updated

2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

conventional arm:conventional radical radiotherapy

adaptive arm:adaptive radiotherapy guided by PET/CT

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age = 18 years at time of signing Informed Consent Form 2.ECOG (Eastern Cooperative Oncology Group) performance status (PS) of 0-1 (See Appendix A) 3.Patients must have pathologically proven non-small cell lung cancer. 4.Patients must have unresectable stage III disease according to TNM classification (UICC 7th ed., 2009) 5.Patients must not have history of antitumor treatment. 6.Patient must have a measurable lesion in pretreatment CT scan of the chest. 7.Patients must have reasonable organ and marrow functions as defined below: - WBC = 3,000/mm3 - Patients must have hemoglobin > 9.0 g/dL. - absolute neutrophil count = 1.5x109/L - platelets = 100 x109/L without transfusion - total bilirubin = 1.5 x upper limit of normal (ULN) - AST (SGOT) and ALT (SGPT) = 2.5 x institutional ULN - creatinine = 1.5 x ULN 8.Signed Informed Consent Form

Exclusion criteria

Exclusion criteria: 1.Mixed small cell and non-small cell cancer 2.Pregnant women are excluded from this study because radiation has the potential for teratogenic or abortifacient effects. 3.NSCLC known to have a mutation in the EGFR gene or an ALK fusion oncogene are excluded from the study. 4.Have interstitial lung disease (ILD), or have a history of ILD and require hormone therapy; 5.Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study; 6.Any condition that, in the opinion of the investigator, would interfere with the evaluation of the study drug or interpretation of patient safety or study results.

Design outcomes

Primary

Measure	Time frame
2-year local-regional tumor control (LRTC);	—

Secondary

Measure	Time frame
PFS;OS;	—

Countries

China

Contacts

Public ContactYaping Xu

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

xuyaping1207@163.com+86 138 1702 5372

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026